Skip to main content

Advertisement

SpringerLink
Log in

Reducing the risk of stroke in type 2 diabetes: pathophysiological and therapeutic perspectives

  • Review
  • Published:
Journal of Neurology Aims and scope Submit manuscript

Abstract

Reducing the excess cerebrovascular burden in patients with type 2 diabetes remains a major therapeutic challenge, especially with respect to the high risk of recurrent events. Targeting the traditional metabolic risk factors of hypertension, dyslipidemia, and hyperglycemia has failed to remove this excess risk, and agents targeting thrombotic risk (i.e., antiplatelet and anticoagulant drugs) remain poorly studied in the context of stroke in diabetes. This may relate to the accumulation of risk factors in type 2 diabetes as well as to diabetes-specific pathophysiologic factors. Regrettably, there is a lack of prospective evidence to support the efficacy of interventions in the secondary prevention of cerebrovascular events in type 2 diabetes, particularly recurrent stroke events. Overall, there is a need for rigorous evaluations of new therapeutic approaches in both primary and secondary prevention of stroke and management of acute stroke in patients with type 2 diabetes. This systematic review of the published literature summarizes the evidence regarding current therapeutic interventions and their impact on the risk of stroke in people with type 2 diabetes, and highlights potential strategies for improving outcomes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358:2545–2559. doi:10.1056/NEJMoa0802743

    Article  PubMed  CAS  Google Scholar 

  2. Adachi H, Hirai Y, Tsuruta M, Fujiura Y, Imaizuml T (2001) Is insulin resistance or diabetes mellitus associated with stroke? An 18-year follow-up study. Diabetes Res Clin Pract 51:215–223. doi:10.1016/S0168-8227(00)00236-9

    Article  PubMed  CAS  Google Scholar 

  3. Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA, Wright AD, Turner RC, Holman R (2000) Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 321:412–419. doi:10.1136/bmj.321.7258.412

    Article  PubMed  CAS  Google Scholar 

  4. ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358:2560–2572. doi:10.1056/NEJMoa0802987

    Article  PubMed  CAS  Google Scholar 

  5. Ajjan R, Storey RF, Grant PJ (2008) Aspirin resistance and diabetes mellitus. Diabetologia 51:385–390. doi:10.1007/s00125-007-0898-3

    Article  PubMed  CAS  Google Scholar 

  6. Ajjan RA, Grant PJ (2008) The cardiovascular safety of rosiglitazone. Expert Opin Drug Saf 7:367–376. doi:10.1517/14740338.7.4.367

    Article  PubMed  CAS  Google Scholar 

  7. Allemann S, Diem P, Egger M, Christ ER, Stettler C (2006) Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus: meta-analysis of randomised controlled trials. Curr Med Res Opin 22:617–623. doi:10.1185/030079906X89865

    Article  PubMed  CAS  Google Scholar 

  8. Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, Rudolph AE, Sillesen H, Simunovic L, Szarek M, Welch KM, Zivin JA, Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators (2006) High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 355:549–559. doi:10.1056/NEJMoa061894

    Article  PubMed  CAS  Google Scholar 

  9. Amarenco P, Goldstein LB, Callahan A 3rd, Sillesen H, Hennerici MG, O’Neill BJ, Rudolph AE, Simunovic L, Zivin JA, Welch KM; on behalf of the SPARCL Investigators (2008) Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Atherosclerosis [Epub ahead of print]

  10. Amarenco P, Labreuche J, Touboul PJ (2008) High-density lipoprotein-cholesterol and risk of stroke and carotid atherosclerosis: a systematic review. Atherosclerosis 196:489–496. doi:10.1016/j.atherosclerosis.2007.07.033

    Article  PubMed  CAS  Google Scholar 

  11. Antithrombotic Trialists’ Collaboration (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324:71–86. doi:10.1136/bmj.324.7336.S71

    Article  Google Scholar 

  12. Arboix A, Rivas A, García-Eroles L, de Marcos L, Massons J, Oliveres M (2005) Cerebral infarction in diabetes: clinical pattern, stroke subtypes, and predictors of in-hospital mortality. BMC Neurol 5:9. doi:10.1186/1471-2377-5-9

    Article  PubMed  Google Scholar 

  13. Athyros VG, Papageorgiou AA, Symeonidis AN, Didangelos TP, Pehlivanidis AN, Bouloukos VI, Mikhailidis DP, GREACE Study Collaborative Group (2003) Early benefit from structured care with atorvastatin in patients with coronary heart disease and diabetes mellitus. Angiology 54:679–690. doi:10.1177/000331970305400607

    Article  PubMed  Google Scholar 

  14. Baalbaki HA, Bell DS (2007) Insulin resistance and thrombogenesis: recent insights and therapeutic implications. Endocr Pract 13:679–686

    PubMed  Google Scholar 

  15. Barrett-Connor E, Khaw KT (1988) Diabetes mellitus: an independent risk factor for stroke? Am J Epidemiol 128:116–123

    PubMed  CAS  Google Scholar 

  16. Barzilay JI, Davis BR, Bettencourt J, Margolis KL, Goff DC Jr, Black H, Habib G, Ellsworth A, Force RW, Wiegmann T, Ciocon JO, Basile JN, ALLHAT Collaborative Research Group (2004) Cardiovascular outcomes using doxazosin vs. chlorthalidone for the treatment of hypertension in older adults with and without glucose disorders: a report from the ALLHAT study. J Clin Hypertens (Greenwich) 6:116–125. doi:10.1111/j.1524-6175.2004.03216.x

    Article  CAS  Google Scholar 

  17. Batty GD, Kivimäki M, Davey Smith G, Marmot MG, Shipley MJ (2008) Post-challenge blood glucose concentration and stroke mortality rates in non-diabetic men in London: 38-year follow-up of the original Whitehall prospective cohort study. Diabetologia 51:1123–1126. doi:10.1007/s00125-008-1005-0

    Article  PubMed  CAS  Google Scholar 

  18. Belch J, MacCuish A, Campbell I, Cobbe S, Taylor R, Prescott R, Lee R, Bancroft J, MacEwan S, Shepherd J, Macfarlane P, Morris A, Jung R, Kelly C, Connacher A, Peden N, Jamieson A, Matthews D, Leese G, McKnight J, O’Brien I, Semple C, Petrie J, Gordon D, Pringle S, MacWalter R, Prevention of Progression of Arterial Disease, Diabetes Study Group, Diabetes Registry Group, Royal College of Physicians Edinburgh (2008) The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 337:a1840

    Article  PubMed  Google Scholar 

  19. Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL, Drury PL, Esmatjes E, Hricik D, Parikh CR, Raz I, Vanhille P, Wiegmann TB, Wolfe BM, Locatelli F, Goldhaber SZ, Lewis EJ, Irbesartan Diabetic Nephropathy Trial, Collaborative Study Group (2003) Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med 138:542–549

    PubMed  CAS  Google Scholar 

  20. Berthet K, Neal BC, Chalmers JP, MacMahon SW, Bousser MG, Colman SA, Woodward M, Perindopril Protection Against Recurrent Stroke Study Collaborative Group (2004) Reductions in the risks of recurrent stroke in patients with and without diabetes: the PROGRESS Trial. Blood Press 13:7–13. doi:10.1080/08037050410029605

    Article  PubMed  Google Scholar 

  21. Betteridge DJ (2008) Lipid lowering in diabetes mellitus. Curr Opin Lipidol 19:579–584. doi:10.1097/MOL.0b013e328314b6b4

    Article  PubMed  CAS  Google Scholar 

  22. Bhatt DL, Marso SP, Hirsch AT, Ringleb PA, Hacke W, Topol EJ (2002) Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol 90:625–628. doi:10.1016/S0002-9149(02)02567-5

    Article  PubMed  Google Scholar 

  23. Blanco M, Moro MA, Dávalos A, Leira R, Castellanos M, Serena J, Vivancos J, Rodríguez-Yáñez M, Lizasoain I, Castillo J (2005) Increased plasma levels of 15-deoxyDelta prostaglandin J2 are associated with good outcome in acute atherothrombotic ischemic stroke. Stroke 36:1189–1194. doi:10.1161/01.STR.0000166054.55993.e5

    Article  PubMed  CAS  Google Scholar 

  24. Boden-Albala B, Cammack S, Chong J, Wang C, Wright C, Rundek T, Elkind MS, Paik MC, Sacco RL (2008) Diabetes, fasting glucose levels, and risk of ischemic stroke and vascular events: findings from the Northern Manhattan Study (NOMAS). Diabetes Care 31(6):1132–1137. doi:10.2337/dc07-0797

    Article  PubMed  Google Scholar 

  25. Bots ML, Elwood PC, Nikitin Y, Salonen JT, Freire de Concalves A, Inzitari D, Sivenius J, Benetou V, Tuomilehto J, Koudstaal PJ, Grobbee DE (2002) Total and HDL cholesterol and risk of stroke. EUROSTROKE: a collaborative study among research centres in Europe. J Epidemiol Community Health 56(Suppl 1):i19–i24. doi:10.1136/jech.56.suppl_1.i19

    Article  PubMed  Google Scholar 

  26. Bowman TS, Sesso HD, Ma J, Kurth T, Kase CS, Stampfer MJ, Gaziano JM (2003) Cholesterol and the risk of ischemic stroke. Stroke 34:2930–2934. doi:10.1161/01.STR.0000102171.91292.DC

    Article  PubMed  CAS  Google Scholar 

  27. Brohall G, Odén A, Fagerberg B (2006) Carotid artery intima-media thickness in patients with Type 2 diabetes mellitus and impaired glucose tolerance: a systematic review. Diabet Med 23:609–616. doi:10.1111/j.1464-5491.2005.01725.x

    Article  PubMed  CAS  Google Scholar 

  28. Brown CM, Marthol H, Zikeli U, Ziegler D, Hilz MJ (2008) A simple deep breathing test reveals altered cerebral autoregulation in type 2 diabetic patients. Diabetologia 51:756–761. doi:10.1007/s00125-008-0958-3

    Article  PubMed  CAS  Google Scholar 

  29. Capes SE, Hunt D, Malmberg K, Pathak P, Gerstein HC (2001) Stress hyperglycemia and prognosis of stroke in nondiabetic and diabetic patients: a systematic overview. Stroke 32:2426–2432. doi:10.1161/hs1001.096194

    Article  PubMed  CAS  Google Scholar 

  30. Carr ME (2001) Diabetes mellitus: a hypercoagulable state. J Diabetes Complicat 15:44–54. doi:10.1016/S1056-8727(00)00132-X

    Article  PubMed  CAS  Google Scholar 

  31. Carter A, Murphy MO, Turner NJ, Halka AT, Ghosh J, Serracino-Inglott F, Walker MG, Syed F (2007) Initimal neovascularisation is a prominent feature of atherosclerotic plaques in diabetic patients with critical limb ischaemia. Eur J Vasc Endovasc Surg 33:319–324. doi:10.1016/j.ejvs.2006.10.021

    Article  PubMed  CAS  Google Scholar 

  32. Cholesterol Treatment Trialists’ (CTT) Collaborators, Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, Armitage J, Baigent C (2008) Efficacy of cholesterol-lowering therapy in 18, 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 371:117–125. doi:10.1016/S0140-6736(08)60104-X

    Article  PubMed  CAS  Google Scholar 

  33. Cipollone F, Iezzi A, Fazia M, Zucchelli M, Pini B, Cuccurullo C, De Cesare D, De Blasis G, Muraro R, Bei R, Chiarelli F, Schmidt AM, Cuccurullo F, Mezzetti A (2003) The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control. Circulation 108:1070–1077. doi:10.1161/01.CIR.0000086014.80477.0D

    Article  PubMed  CAS  Google Scholar 

  34. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH, CARDS investigators (2004) Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebo-controlled trial. Lancet 364:685–696. doi:10.1016/S0140-6736(04)16895-5

    Article  PubMed  CAS  Google Scholar 

  35. Collino M, Aragno M, Mastrocola R, Gallicchio M, Rosa AC, Dianzani C, Danni O, Thiemermann C, Fantozzi R (2006) Modulation of the oxidative stress and inflammatory response by PPAR-gamma agonists in the hippocampus of rats exposed to cerebral ischemia/reperfusion. Eur J Pharmacol 530:70–80. doi:10.1016/j.ejphar.2005.11.049

    Article  PubMed  CAS  Google Scholar 

  36. Curb JD, Pressel SL, Cutler JA, Savage PJ, Applegate WB, Black H, Camel G, Davis BR, Frost PH, Gonzalez N, Guthrie G, Oberman A, Rutan GH, Stamler J (1996) Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA 276:1886–1892. doi:10.1001/jama.276.23.1886

    Article  PubMed  CAS  Google Scholar 

  37. Dandona P, Chaudhuri A, Ghanim H, Mohanty P (2007) Proinflammatory effects of glucose and anti-inflammatory effect of insulin: relevance to cardiovascular disease. Am J Cardiol 99:15B–26B. doi:10.1016/j.amjcard.2006.11.003

    Article  PubMed  CAS  Google Scholar 

  38. Davidson M, Meyer PM, Haffner S, Feinstein S, D’Agostino R Sr, Kondos GT, Perez A, Chen Z, Mazzone T (2008) Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with type 2 diabetes mellitus. Circulation 117:2123–2130. doi:10.1161/CIRCULATIONAHA.107.746610

    Article  PubMed  CAS  Google Scholar 

  39. Davis TM, Millns H, Stratton IM, Holman RR, Turner RC (1999) Risk factors for stroke in type 2 diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS) 29. Arch Intern Med 159:1097–1103. doi:10.1001/archinte.159.10.1097

    Article  PubMed  CAS  Google Scholar 

  40. de Jong G, van Raak L, Kessels F, Lodder J (2003) Stroke subtype and mortality. A follow-up study in 998 patients with a first cerebral infarct. J Clin Epidemiol 56:262–268. doi:10.1016/S0895-4356(02)00572-3

    Article  PubMed  Google Scholar 

  41. Delahoy PJ, Magliano DJ, Webb K, Grobler M, Liew D (2009) The relationship between reduction in low-density lipoprotein cholesterol by statins and reduction in risk of cardiovascular outcomes: an updated meta-analysis. Clin Ther 31:236–244. doi:10.1016/j.clinthera.2009.02.017

    Article  PubMed  CAS  Google Scholar 

  42. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefèbvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Korányi L, Laakso M, Mokán M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J, PROactive investigators (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366:1279–1289. doi:10.1016/S0140-6736(05)67528-9

    Article  PubMed  CAS  Google Scholar 

  43. Ebrahim S, Sung J, Song Y-M, Ferrer R, Lawlor DA, Davey Smith G (2006) Serum cholesterol, haemorrhagic stroke, ischaemic stroke, and myocardial infarction: Korean national health system prospective cohort study. BMJ 333:22. doi:10.1136/bmj.38855.610324.80

    Article  PubMed  Google Scholar 

  44. Erdmann E, Dormandy JA, Charbonnel B, Massi-Benedetti M, Moules IK, Skene AM, PROactive Investigators (2007) The effect of pioglitazone on recurrent myocardial infarction in 2, 445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) study. J Am Coll Cardiol 49:1772–1780. doi:10.1016/j.jacc.2006.12.048

    Article  PubMed  CAS  Google Scholar 

  45. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW (1998) The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 338:645–652. doi:10.1056/NEJM199803053381003

    Article  PubMed  CAS  Google Scholar 

  46. Gaede P, Lund-Andersen H, Parving HH, Pedersen O (2008) Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 358:580–591. doi:10.1056/NEJMoa0706245

    Article  PubMed  CAS  Google Scholar 

  47. Gæde P, Pedersen O (2004) Intensive integrated therapy of type 2 diabetes: implications for long-term prognosis. Diabetes 53(Suppl 3):S39–S47. doi:10.2337/diabetes.53.suppl_3.S39

    Article  PubMed  Google Scholar 

  48. Garg R, Chaudhuri A, Munschauer F, Dandona P (2006) Hyperglycemia, insulin, and acute ischemic stroke: a mechanistic justification for a trial of insulin infusion therapy. Stroke 37:267–273. doi:10.1161/01.STR.0000195175.29487.30

    Article  PubMed  CAS  Google Scholar 

  49. Gentile NT, Vaidyula VR, Kanamalla U, DeAngelis M, Gaughan J, Rao AK (2007) Factor VIIa and tissue factor procoagulant activity in diabetes mellitus after acute ischemic stroke: impact of hyperglycemia. Thromb Haemost 98:1007–1013

    PubMed  CAS  Google Scholar 

  50. Goldberg RB, Mellies MJ, Sacks FM, Moyé LA, Howard BV, Howard WJ, Davis BR, Cole TG, Pfeffer MA, Braunwald E (1998) Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels. Subgroup analyses in the cholesterol and recurrent events (CARE) trial. Circulation 98:2513–2519

    PubMed  CAS  Google Scholar 

  51. Grant PJ (2007) Diabetes mellitus as a prothrombotic condition. J Intern Med 262:157–172. doi:10.1111/j.1365-2796.2007.01824.x

    Article  PubMed  CAS  Google Scholar 

  52. Gray CS, Hildreth AJ, Sandercock PA, O’Connell JE, Johnston DE, Cartlidge NE, Bamford JM, James OF, Alberti KG, GIST Trialists Collaboration (2007) Glucose–potassium-insulin infusions in the management of post-stroke hyperglycaemia: the UK Glucose Insulin in Stroke Trial (GIST-UK). Lancet Neurol 6:397–406. doi:10.1016/S1474-4422(07)70080-7

    Article  PubMed  CAS  Google Scholar 

  53. Hansson L, Hedner T, Lund-Johansen P, Kjeldsen SE, Lindholm LH, Syvertsen JO, Lanke J, de Faire U, Dahlöf B, Karlberg BE (2000) Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 356:359–365. doi:10.1016/S0140-6736(00)02526-5

    Article  PubMed  CAS  Google Scholar 

  54. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, Ménard J, Rahn KH, Wedel H, Westerling S (1998) Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 351:1755–1762. doi:10.1016/S0140-6736(98)04311-6

    Article  PubMed  CAS  Google Scholar 

  55. Harmsen P, Lappas G, Rosengren A, Wilhelmsen L (2006) Long-term risk factors for stroke: twenty-eight years of follow-up of 7457 middle-aged men in Goteborg, Sweden. Stroke 37:1663–1667. doi:10.1161/01.STR.0000226604.10877.fc

    Article  PubMed  Google Scholar 

  56. Hart CL, Hole DJ, Smith GD (1999) Risk factors and 20-year stroke mortality in men and women in the Renfrew/Paisley study in Scotland. Stroke 30:1999–2007

    PubMed  CAS  Google Scholar 

  57. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators (2000) Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 355:253–259. doi:10.1016/S0140-6736(99)12323-7

    Article  Google Scholar 

  58. Heart Protection Study Collaborative Group (2003) MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361:2005–2016. doi:10.1016/S0140-6736(03)13636-7

    Article  CAS  Google Scholar 

  59. Ho JE, Paultre F, Mosca L, Women’s Pooling Project (2003) Is diabetes mellitus a cardiovascular disease risk equivalent for fatal stroke in women? Data from the Women’s Pooling Project. Stroke 34:2812–2816. doi:10.1161/01.STR.0000102901.41780.5C

    Article  PubMed  Google Scholar 

  60. Holme I, Aastveit AH, Hammar N, Jungner I, Walldius G (2009) Relationships between lipoprotein components and risk of ischaemic and haemorrhagic stroke in the Apolipoprotein MOrtality RISk study (AMORIS). J Intern Med 265:275–287. doi:10.1111/j.1365-2796.2008.02016.x

    Article  PubMed  CAS  Google Scholar 

  61. Hu G, Jousilahti P, Sarti C, Antikainen R, Tuomilehto J (2006) The effect of diabetes and stroke at baseline and during follow-up on stroke mortality. Diabetologia 49:2309–2316. doi:10.1007/s00125-006-0378-1

    Article  PubMed  CAS  Google Scholar 

  62. Hu G, Sarti C, Jousilahti P, Peltonen M, Qiao Q, Antikainen R, Tuomilehto J (2005) The impact of history of hypertension and type 2 diabetes at baseline on the incidence of stroke and stroke mortality. Stroke 36:2538–2543. doi:10.1161/01.STR.0000190894.30964.75

    Article  PubMed  Google Scholar 

  63. Hui L, Pei DS, Zhang QG, Guan QH, Zhang GY (2005) The neuroprotection of insulin on ischemic brain injury in rat hippocampus through negative regulation of JNK signaling pathway by PI3K/Akt activation. Brain Res 1052:1–9. doi:10.1016/j.brainres.2005.05.043

    Article  PubMed  CAS  Google Scholar 

  64. IDF Clinical Guidelines Task Force (2005) Global guideline for type 2 diabetes. International Diabetes Federation, Brussels

    Google Scholar 

  65. Janghorbani M, Hu FB, Willett WC, Li TY, Manson JE, Logroscino G, Rexrode KM (2007) Prospective study of type 1 and type 2 diabetes and risk of stroke subtypes: the Nurses’ Health Study. Diabetes Care 30:1730–1735. doi:10.2337/dc06-2363

    Article  PubMed  Google Scholar 

  66. Kario K, Ishikawa J, Hoshide S, Matsui Y, Morinari M, Eguchi K, Ishikawa S, Shimada K (2005) Diabetic brain damage in hypertension: role of renin-angiotensin system. Hypertension 45:887–893. doi:10.1161/01.HYP.0000163460.07639.3f

    Article  PubMed  CAS  Google Scholar 

  67. Keech A, Colquhoun D, Best J, Kirby A, Simes RJ, Hunt D, Hague W, Beller E, Arulchelvam M, Baker J, Tonkin A, LIPID Study Group (2003) Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. Diabetes Care 26:2713–2721. doi:10.2337/diacare.26.10.2713

    Article  PubMed  CAS  Google Scholar 

  68. Keech A, Colquhoun D, Best J, Kirby A, Simes RJ, Hunt D, Hague W, Beller E, Arulchelvam M, Baker J, Tonkin A, LIPID Study Group (2002) Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch Intern Med 162:2597–2604. doi:10.1001/archinte.162.22.2597

    Article  Google Scholar 

  69. Kernan WN, Inzucchi SE, Viscoli CM, Brass LM, Bravata DM, Horwitz RI (2002) Insulin resistance and risk for stroke. Neurology 59:809–815

    PubMed  CAS  Google Scholar 

  70. Kissela BM, Khoury J, Kleindorfer D, Woo D, Schneider A, Alwell K, Miller R, Ewing I, Moomaw CJ, Szaflarski JP, Gebel J, Shukla R, Broderick JP (2005) Epidemiology of ischemic stroke in patients with diabetes: the greater Cincinnati/Northern Kentucky Stroke Study. Diabetes Care 28:355–359. doi:10.2337/diacare.28.2.355

    Article  PubMed  Google Scholar 

  71. Knopp RH, d’Emden M, Smilde JG, Pocock SJ (2006) Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care 29:1478–1485. doi:10.2337/dc05-2415

    Article  PubMed  CAS  Google Scholar 

  72. Koren-Morag N, Tanne D, Graff E, Goldbourt U (2002) Low- and high-density lipoprotein cholesterol and ischemic cerebrovascular disease: the bezafibrate infarction prevention registry. Arch Intern Med 162:993–999. doi:10.1001/archinte.162.9.993

    Article  PubMed  CAS  Google Scholar 

  73. Lakshminarayan K, Anderson DC, Herzog CA, Qureshi AI (2008) Clinical epidemiology of atrial fibrillation and related cerebrovascular events in the United States. Neurologist 14:143–150. doi:10.1097/NRL.0b013e31815cffae

    Article  PubMed  Google Scholar 

  74. Lee J, Reding M (2007) Effects of thiazolidinediones on stroke recovery: a case-matched controlled study. Neurochem Res 32:635–638. doi:10.1007/s11064-006-9138-3

    Article  PubMed  CAS  Google Scholar 

  75. Lehto S, Rönnemaa T, Pyörälä K, Laakso M (1996) Predictors of stroke in middle-aged patients with non-insulin-dependent diabetes. Stroke 27:63–68

    PubMed  CAS  Google Scholar 

  76. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE (2007) Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 298:1180–1188. doi:10.1001/jama.298.10.1180

    Article  PubMed  CAS  Google Scholar 

  77. Lindholm LH, Hansson L, Ekbom T, Dahlöf B, Lanke J, Linjer E, Scherstén B, Wester PO, Hedner T, de Faire U (2000) Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: results from the Swedish Trial in Old Patients with Hypertension-2. STOP Hypertension-2 Study Group. J Hypertens 18:1671–1675. doi:10.1097/00004872-200018110-00020

    Article  PubMed  CAS  Google Scholar 

  78. Lindholm LH, Ibsen H, Borch-Johnsen K, Olsen MH, Wachtell K, Dahlöf B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristianson K, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wedel H, Aurup P, Edelman JM, Snapinn S, For the LIFE study group (2002) Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens 20:1879–1886. doi:10.1097/00004872-200209000-00035

    Article  PubMed  CAS  Google Scholar 

  79. Luo Y, Yin W, Signore AP, Zhang F, Hong Z, Wang S, Graham SH, Chen J (2006) Neuroprotection against focal ischemic brain injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. J Neurochem 97:435–448. doi:10.1111/j.1471-4159.2006.03758.x

    Article  PubMed  CAS  Google Scholar 

  80. Mancia G, Brown M, Castaigne A, de Leeuw P, Palmer CR, Rosenthal T, Wagener G, Ruilope LM, INSIGHT (2003) Outcomes with nifedipine GITS or Co-amilozide in hypertensive diabetics and nondiabetics in Intervention as a Goal in Hypertension (INSIGHT). Hypertension 41:431–436. doi:10.1161/01.HYP.0000057420.27692.AD

    Article  PubMed  CAS  Google Scholar 

  81. Mankovsky BN, Ziegler D (2004) Stroke in patients with diabetes mellitus. Diabetes Metab Res Rev 20:268–287. doi:10.1002/dmrr.490

    Article  PubMed  Google Scholar 

  82. Marre M, Lievre M, Chatellier G, Mann JF, Passa P, Ménard J, DIABHYCAR Study Investigators (2004) Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study). BMJ 328:495. doi:10.1136/bmj.37970.629537.0D

    Article  PubMed  CAS  Google Scholar 

  83. Mazighi M, Labreuche J, Gongora-Rivera F, Duyckaerts C, Hauw JJ, Amarenco P (2008) Autopsy prevalence of intracranial atherosclerosis in patients with fatal stroke. Stroke 39:1142–1147. doi:10.1161/STROKEAHA.107.496513

    Article  PubMed  Google Scholar 

  84. Mazzone T, Meyer PM, Feinstein SB, Davidson MH, Kondos GT, D’Agostino RB Sr, Perez A, Provost JC, Haffner SM (2006) Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 296:2572–2581. doi:10.1001/jama.296.21.joc60158

    Article  PubMed  CAS  Google Scholar 

  85. Megherbi SE, Milan C, Minier D, Couvreur G, Osseby GV, Tilling K, Di Carlo A, Inzitari D, Wolfe CD, Moreau T, Giroud M, European BIOMED Study of Stroke Care Group (2003) Association between diabetes and stroke subtype on survival and functional outcome 3 months after stroke: data from the European BIOMED Stroke Project. Stroke 34:688–694. doi:10.1161/01.STR.0000057975.15221.40

    Article  PubMed  Google Scholar 

  86. Moreno PR, Murcia AM, Palacios IF, Leon MN, Bernardi VH, Fuster V, Fallon JT (2000) Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus. Circulation 102:2180–2184

    PubMed  CAS  Google Scholar 

  87. Myint PK, Sinha S, Wareham NJ, Bingham SA, Luben RN, Welch AA, Khaw KT (2007) Glycated hemoglobin and risk of stroke in people without known diabetes in the European Prospective Investigation into Cancer (EPIC)–Norfolk prospective population study: a threshold relationship? Stroke 38:271–275. doi:10.1161/01.STR.0000254549.75763.5f

    Article  PubMed  CAS  Google Scholar 

  88. Nakamura T, Yamamoto E, Kataoka K, Yamashita T, Tokutomi Y, Dong YF, Matsuba S, Ogawa H, Kim-Mitsuyama S (2007) Pioglitazone exerts protective effects against stroke in stroke-prone spontaneously hypertensive rats, independently of blood pressure. Stroke 38:3016–3022. doi:10.1161/STROKEAHA.107.486522

    Article  PubMed  CAS  Google Scholar 

  89. Natali A, Toschi E, Baldeweg S, Ciociaro D, Favilla S, Saccà L, Ferrannini E (2006) Clustering of insulin resistance with vascular dysfunction and low-grade inflammation in type 2 diabetes. Diabetes 55:1133–1140. doi:10.2337/diabetes.55.04.06.db05-1076

    Article  PubMed  CAS  Google Scholar 

  90. Nigro J, Osman N, Dart AM, Little PJ (2006) Insulin resistance and atherosclerosis. Endocr Rev 27:242–259. doi:10.1210/er.2005-0007

    Article  PubMed  CAS  Google Scholar 

  91. Niskanen L, Hedner T, Hansson L, Lanke J, Niklason A, CAPPP Study Group (2001) Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/beta-blocker-based treatment regimen: a subanalysis of the Captopril Prevention Project. Diabetes Care 24:2091–2096. doi:10.2337/diacare.24.12.2091

    Article  PubMed  CAS  Google Scholar 

  92. Nissen SE, Nicholls SJ, Wolski K, Nesto R, Kupfer S, Perez A, Jure H, De Larochellière R, Staniloae CS, Mavromatis K, Saw J, Hu B, Lincoff AM, PERISCOPE Tuzcu EM Investigators (2008) Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes, The PERISCOPE randomized controlled trial. JAMA 299:1561–1573. doi:10.1001/jama.299.13.1561

    Article  PubMed  CAS  Google Scholar 

  93. Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N, Jinnouchi H, Sugiyama S, Saito Y, Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Investigators (2008) Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 300:2134–2141. doi:10.1001/jama.2008.623

    Article  PubMed  CAS  Google Scholar 

  94. Paciaroni M, Hennerici M, Agnelli G, Bogousslavsky J (2007) Statins and stroke prevention. Cerebrovasc Dis 24:170–182. doi:10.1159/000104474

    Article  PubMed  CAS  Google Scholar 

  95. Patel A, Woodward M, Campbell DJ, Sullivan DR, Colman S, Chalmers J, Neal B, MacMahon S (2005) Plasma lipids predict myocardial infarction, but not stroke, in patients with established cerebrovascular disease. Eur Heart J 26:1910–1915. doi:10.1093/eurheartj/ehi407

    Article  PubMed  CAS  Google Scholar 

  96. Patel A, ADVANCE Collaborative Group, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, Harrap S, Poulter N, Marre M, Cooper M, Glasziou P, Grobbee DE, Hamet P, Heller S, Liu LS, Mancia G, Mogensen CE, Pan CY, Rodgers A, Williams B (2007) Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 370:340–829. doi:10.1016/S0140-6736(07)61303-8

    Google Scholar 

  97. PROGRESS Collaborative Group (2001) Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 358:1033–1041. doi:10.1016/S0140-6736(01)06178-5

    Article  Google Scholar 

  98. Prospective Studies Collaboration, Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J, Qizilbash N, Peto R, Collins R (2007) Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 370:1829–1839. doi:10.1016/S0140-6736(07)61778-4

    Article  PubMed  CAS  Google Scholar 

  99. Ringleb PA (2008) Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 25:457–507. doi:10.1159/000131083

    Article  Google Scholar 

  100. Rizk NN, Rafols J, Dunbar JC (2006) Cerebral ischemia-induced apoptosis and necrosis in normal and diabetic rats: effects of insulin and C-peptide. Brain Res 1096:204–212. doi:10.1016/j.brainres.2006.04.060

    Article  PubMed  CAS  Google Scholar 

  101. Rizzo M, Corrado E, Coppola G, Muratori I, Novo G, Novo S (2008) Prediction of cardio- and cerebro-vascular events in patients with subclinical carotid atherosclerosis and low HDL-cholesterol. Atherosclerosis 200:389–395. doi:10.1016/j.atherosclerosis.2007.12.020

    Article  PubMed  CAS  Google Scholar 

  102. Roccatagliata D, Avanzini F, Monesi L, Caimi V, Lauri D, Longoni P, Marchioli R, Tombesi M, Tognoni G, Roncaglioni MC, Collaborative Group Risk Prevention Study (2006) Is global cardiovascular risk considered in current practice? Treatment and control of hypertension, hyperlipidemia, and diabetes according to patients’ risk level. Vasc Health Risk Manag 2:507–514. doi:10.2147/vhrm.2006.2.4.507

    Article  PubMed  Google Scholar 

  103. Rodondi N, Peng T, Karter AJ, Bauer DC, Vittinghoff E, Tang S, Pettitt D, Kerr EA, Selby JV (2006) Therapy modifications in response to poorly controlled hypertension, dyslipidemia, and diabetes mellitus. Ann Intern Med 144:475–484

    PubMed  Google Scholar 

  104. Rohr J, Kittner S, Feeser B, Hebel JR, Whyte MG, Weinstein A, Kanarak N, Buchholz D, Earley C, Johnson C, Macko R, Price T, Sloan M, Stern B, Wityk R, Wozniak M, Sherwin R (1996) Traditional risk factors and ischemic stroke in young adults: the Baltimore–Washington Cooperative Young Stroke Study. Arch Neurol 53:603–607

    PubMed  CAS  Google Scholar 

  105. Romera C, Hurtado O, Mallolas J, Pereira MP, Morales JR, Romera A, Serena J, Vivancos J, Nombela F, Lorenzo P, Lizasoain I, Moro MA (2007) Ischemic preconditioning reveals that GLT1/EAAT2 glutamate transporter is a novel PPARgamma target gene involved in neuroprotection. J Cereb Blood Flow Metab 27:1327–1338. doi:10.1038/sj.jcbfm.9600438

    Article  PubMed  CAS  Google Scholar 

  106. Rosvall M, Janzon L, Berglund G, Engström G, Hedblad B (2005) Incidence of stroke is related to carotid IMT even in the absence of plaque. Atherosclerosis 179:325–331. doi:10.1016/j.atherosclerosis.2004.10.015

    Article  PubMed  CAS  Google Scholar 

  107. Rubins HB, Robins SJ, Collins D, Nelson DB, Elam MB, Schaefer EJ, Faas FH, Anderson JW (2002) Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch Intern Med 162:2597–2604. doi:10.1001/archinte.162.22.2597

    Article  PubMed  CAS  Google Scholar 

  108. Rydén L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, de Boer MJ, Cosentino F, Jönsson B, Laakso M, Malmberg K, Priori S, Ostergren J, Tuomilehto J, Thrainsdottir I, Vanhorebeek I, Stramba-Badiale M, Lindgren P, Qiao Q, Priori SG, Blanc JJ, Budaj A, Camm J, Dean V, Deckers J, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo J, Zamorano JL, Deckers JW, Bertrand M, Charbonnel B, Erdmann E, Ferrannini E, Flyvbjerg A, Gohlke H, Juanatey JR, Graham I, Monteiro PF, Parhofer K, Pyörälä K, Raz I, Schernthaner G, Volpe M, Wood D, Task Force on Diabetes, Cardiovascular Diseases of the European Society of Cardiology (ESC) European Association for the Study of Diabetes (EASD) (2007) Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary, The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 28:88–136. doi:10.1093/eurheartj/ehm124

    Article  PubMed  Google Scholar 

  109. Sacco M, Pellegrini F, Roncaglioni MC, Avanzini F, Tognoni G, Nicolucci A, Collaborative Group PPP (2003) Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care 26:3264–3272. doi:10.2337/diacare.26.12.3264

    Article  PubMed  CAS  Google Scholar 

  110. Scarpello JH (2003) Improving survival with metformin: the evidence base today. Diabetes Metab 29(4 Pt 2):S36–S43

    Google Scholar 

  111. Schmittdiel JA, Uratsu CS, Karter AJ, Heisler M, Subramanian U, Mangione CM, Selby JV (2008) Why don’t diabetes patients achieve recommended risk factor targets? Poor adherence versus lack of treatment intensification. J Gen Intern Med 23:588–594. doi:10.1007/s11606-008-0554-8

    Article  PubMed  Google Scholar 

  112. Schrier RW, Estacio RO, Esler A, Mehler P (2002) Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 61:1086–1097. doi:10.1046/j.1523-1755.2002.00213.x

    Article  PubMed  Google Scholar 

  113. Selvin E, Coresh J, Shahar E, Zhang L, Steffes M, Sharrett AR (2005) Glycaemia (haemoglobin A1c) and incident ischaemic stroke: the Atherosclerosis Risk in Communities (ARIC) Study. Lancet Neurol 4:821–826. doi:10.1016/S1474-4422(05)70227-1

    Article  PubMed  CAS  Google Scholar 

  114. Sever PS, Poulter NR, Dahlöf B, Wedel H, Collins R, Beevers G, Caulfield M, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O’Brien E, Ostergren J (2005) Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial–lipid-lowering arm (ASCOT-LLA). Diabetes Care 28:1151–1157. doi:10.2337/diacare.28.5.1151

    Article  PubMed  CAS  Google Scholar 

  115. Shahar E, Chambless LE, Rosamond WD, Boland LL, Ballantyne CM, McGovern PG, Sharrett AR, Atherosclerosis Risk in Communities Study (2003) Plasma lipid profile and incident ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) study. Stroke 34:623–631. doi:10.1161/01.STR.0000057812.51734.FF

    Article  PubMed  Google Scholar 

  116. Shepherd J, Barter P, Carmena R, Deedwania P, Fruchart JC, Haffner S, Hsia J, Breazna A, LaRosa J, Grundy S, Waters D (2006) Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care 29:1220–1226. doi:10.2337/dc05-2465

    Article  PubMed  CAS  Google Scholar 

  117. Shinohara Y, Gotoh F, Tohgi H, Hirai S, Terashi A, Fukuuchi Y, Otomo E, Itoh E, Matsuda T, Sawada T, Yamaguchi T, Nishimaru K, Ohashi Y (2008) Antiplatelet cilostazol is beneficial in diabetic and/or hypertensive ischemic stroke patients, Subgroup analysis of the cilostazol stroke prevention study. Cerebrovasc Dis 26:63–70. doi:10.1159/000135654

    Article  PubMed  CAS  Google Scholar 

  118. Singer DE, Albers GW, Dalen JE, Go AS, Halperin JL, Manning WJ (2004) Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126(Suppl 3):429S–456S. doi:10.1378/chest.126.3_suppl.429S

    Article  PubMed  CAS  Google Scholar 

  119. Smith PJ, Hurlen M, Abdelnoor M, Arnesen H (2008) Less benefit from warfarin in diabetics after myocardial infarction? Cardiology 111:161–166. doi:10.1159/000121598

    Article  PubMed  CAS  Google Scholar 

  120. Stettler C, Allemann S, Jüni P, Cull CA, Holman RR, Egger M, Krähenbühl S, Diem P (2006) Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: meta-analysis of randomized trials. Am Heart J 152:27–38. doi:10.1016/j.ahj.2005.09.015

    Article  PubMed  CAS  Google Scholar 

  121. Stevens RJ, Coleman RL, Adler AI, Stratton IM, Matthews DR, Holman RR (2004) Risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes: UKPDS 66. Diabetes Care 27:201–207. doi:10.2337/diacare.27.1.201

    Article  PubMed  Google Scholar 

  122. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR (2000) Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:405–412. doi:10.1136/bmj.321.7258.405

    Article  PubMed  CAS  Google Scholar 

  123. Stratton IM, Cull CA, Adler AI, Matthews DR, Neil HA, Holman RR (2006) Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75). Diabetologia 49:1761–1769. doi:10.1007/s00125-006-0297-1

    Article  PubMed  CAS  Google Scholar 

  124. Stroke Risk Working Group in Atrial Fibrillation (2007) Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology 69:546–554. doi:10.1212/01.wnl.0000267275.68538.8d

    Article  Google Scholar 

  125. Tanne D, Koren-Morag N, Graff E, Goldbourt U (2001) Blood lipids and first-ever ischemic stroke/transient ischemic attack in the Bezafibrate Infarction Prevention (BIP) Registry: high triglycerides constitute an independent risk factor. Circulation 104:2892–2897. doi:10.1161/hc4901.100384

    Article  PubMed  CAS  Google Scholar 

  126. Tatti P, Pahor M, Byington RP, Di Mauro P, Guarisco R, Strollo G, Strollo F (1998) Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 21:597–603. doi:10.2337/diacare.21.4.597

    Article  PubMed  CAS  Google Scholar 

  127. Tirschwell DL, Smith NL, Heckbert SR, Lemaitre RN, Longstreth WT Jr, Psaty BM (2004) Association of cholesterol with stroke risk varies in stroke subtypes and patient subgroups. Neurology 63:1868–1875

    PubMed  CAS  Google Scholar 

  128. Tuomilehto J, Rastenyte D, Jousilahti P, Sarti C, Vartiainen E (1996) Diabetes mellitus as a risk factor for death from stroke. Prospective study of the middle-aged Finnish population. Stroke 27:210–215

    PubMed  CAS  Google Scholar 

  129. Tureyen K, Kapadia R, Bowen KK, Satriotomo I, Liang J, Feinstein DL, Vemuganti R (2007) Peroxisome proliferator-activated receptor-gamma agonists induce neuroprotection following transient focal ischemia in normotensive, normoglycemic as well as hypertensive and type-2 diabetic rodents. J Neurochem 101:41–56. doi:10.1111/j.1471-4159.2006.04376.x

    Article  PubMed  CAS  Google Scholar 

  130. Turnbull F, Neal B, Algert C, Chalmers J, Chapman N, Cutler J, Woodward M, MacMahon S, Blood Pressure Lowering Treatment Trialists’ Collaboration (2005) Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 165:1410–1419. doi:10.1001/archinte.165.12.1410

    Article  PubMed  Google Scholar 

  131. Tuttolomondo A, Pinto A, Salemi G, Di Raimondo D, Di Sciacca R, Fernandez P, Ragonese P, Savettieri G, Licata G (2008) Diabetic and non-diabetic subjects with ischemic stroke: differences, subtype distribution and outcome. Nutr Metab Cardiovasc Dis 18:152–157. doi:10.1016/j.numecd.2007.02.003

    Article  PubMed  Google Scholar 

  132. UKPDS Group (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854–865. doi:10.1016/S0140-6736(98)07037-8

    Article  Google Scholar 

  133. UKPDS Group (1998) Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 317:713–720

    Google Scholar 

  134. UKPDS Group (1998) Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837–853. doi:10.1016/S0140-6736(98)07019-6

    Article  Google Scholar 

  135. UKPDS Group (1998) Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317:703–713

    Google Scholar 

  136. US Department of Health and Human Services National Heart, Lung and Blood Institute (2004) The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. NIH Publication No. 04-5230 (Available at: http://www.nhlbi.nih.gov/guidelines/hypertension/. Last accessed 1 April 2009)

  137. Vivancos-Mora J, Gil-Núñez AC (2005) Lipids and stroke: the opportunity of lipid-lowering treatment. Cerebrovasc Dis 20(Suppl 2):53–67. doi:10.1159/000089357

    Article  PubMed  CAS  Google Scholar 

  138. Wanner C, Krane V, März W, Olschewski M, Mann JF, Ruf G, Ritz E, German Diabetes Dialysis Study Investigators (2005) Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353:238–248. doi:10.1056/NEJMoa043545

    Article  PubMed  CAS  Google Scholar 

  139. Watala C, Boncler M, Gresner P (2005) Blood platelet abnormalities and pharmacological modulation of platelet reactivity in patients with diabetes mellitus. Pharmacol Rep 57(suppl):42–58

    PubMed  Google Scholar 

  140. Whelton PK, Barzilay J, Cushman WC (2005) Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 165:1401–1409. doi:10.1001/archinte.165.12.1401

    Article  PubMed  CAS  Google Scholar 

  141. Wilcox R, Bousser MG, Betteridge DJ, Schernthaner G, Pirags V, Kupfer S, Dormandy J, PROactive Investigators (2007) Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke 38:865–873. doi:10.1161/01.STR.0000257974.06317.49

    Article  PubMed  CAS  Google Scholar 

  142. Woodward M, Zhang X, Barzi F, Pan W, Ueshima H, Rodgers A, MacMahon S, Asia Pacific Cohort Studies Collaboration (2003) The effects of diabetes on the risks of major cardiovascular diseases and death in the Asia-Pacific region. Diabetes Care 26:360–366. doi:10.2337/diacare.26.2.360

    Article  PubMed  CAS  Google Scholar 

  143. You RX, McNeil JJ, O’Malley HM, Davis SM, Thrift AG, Donnan GA (1997) Risk factors for stroke due to cerebral infarction in young adults. Stroke 28:1913–1918

    PubMed  CAS  Google Scholar 

  144. Yui Y, Sumiyoshi T, Kodama K, Hirayama A, Nonogi H, Kanmatsuse K, Origasa H, Iimura O, Ishii M, Saruta T, Arakawa K, Hosoda S, Kawai C (2004) Nifedipine retard was as effective as angiotensin converting enzyme inhibitors in preventing cardiac events in high-risk hypertensive patients with diabetes and coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) subgroup analysis. Hypertens Res 27:449–456. doi:10.1291/hypres.27.449

    Article  PubMed  CAS  Google Scholar 

  145. Yusuf S, Diener HC, Sacco RL, Cotton D, Ounpuu S, Lawton WA, Palesch Y, Martin RH, Albers GW, Bath P, Bornstein N, Chan BP, Chen ST, Cunha L, Dahlöf B, De Keyser J, Donnan GA, Estol C, Gorelick P, Gu V, Hermansson K, Hilbrich L, Kaste M, Lu C, Machnig T, Pais P, Roberts R, Skvortsova V, Teal P, Toni D, VanderMaelen C, Voigt T, Weber M, Yoon BW, PRoFESS Study Group (2008) Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 359:1225–1237. doi:10.1056/NEJMoa0804593

    Article  PubMed  CAS  Google Scholar 

  146. Zhao CX, Cui YH, Fan Q, Wang PH, Hui R, Cianflone K, Wang DW (2009) Small dense low-density lipoproteins and associated risk factors in patients with stroke. Cerebrovasc Dis 27:99–104. doi:10.1159/000175768

    Article  PubMed  CAS  Google Scholar 

  147. Zhao Y, Patzer A, Herdegen T, Gohlke P, Culman J (2006) Activation of cerebral peroxisome proliferator-activated receptors gamma promotes neuroprotection by attenuation of neuronal cyclooxygenase-2 overexpression after focal cerebral ischemia in rats. FASEB J 20:1162–1175. doi:10.1096/fj.05-5007com

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Medical Park Hospital, Thanngasse 15, 83483, Bischofswiesen, Germany

    Dirk Sander

  2. Department of Neurology, University of Technology, Ismaninger Strasse 22, 81675, Munich, Germany

    Dirk Sander

  3. The LIGHT Laboratories, Institute for Genetics, Health and Therapeutics, University of Leeds, Leeds, UK

    Mark T. Kearney

Authors
  1. Dirk Sander
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mark T. Kearney
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dirk Sander.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sander, D., Kearney, M.T. Reducing the risk of stroke in type 2 diabetes: pathophysiological and therapeutic perspectives. J Neurol 256, 1603–1619 (2009). https://doi.org/10.1007/s00415-009-5143-1

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-009-5143-1

Keywords

Search

Navigation